Tardive Dyskinesia and Psychiatric Illness

Download All
Access these interactive, online programs designed to provide the care team with the resources and practical guidance they need to apply the most recent data, guidelines, and expert recommendations for the personalized treatment of their patients with tardive dyskinesia.
Rif S. El-Mallakh, MD
Joseph P. McEvoy, MD
Jonathan M. Meyer, MD


The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.

Joseph P. McEvoy, MD Released: May 4, 2021

Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.

Rif S. El-Mallakh, MD Released: June 8, 2021

Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Jonathan M. Meyer, MD Released: July 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.